--- title: "The Evidence-Base for Neurofeedback as a Reimbursable Healthcare Service to Treat Attention Deficit/Hyperactivity Disorder By H. Edmund Pigott, Ph.D.,a Lindsay De Biase, Ph.D.,b Eugenia Bodenhamer-Davis, Ph.D.c & Richard E. Davis, M.S.d" description: "[The Evidence-Base for Neurofeedback as a Reimbursable Healthcare Service to Treat Attention Deficit/Hyperactivity Disorder By H. Edmund Pigott, Ph.D.,a Lindsay De Biase, Ph.D.,b Eugenia Bodenhamer-Davis, Ph.D.c & Richard E. Davis, M.S.d.pdf](https://isnr.org/wp-content/uploads/2019/07/NFB-as-an-Evidence-Based-Treatment-for-ADHD.pdf) *Disclaimer: The content below was generated with the assistance…" url: "https://brainmaster.com/kb-entry/the-evidence-base-for-neurofeedback-as-a-reimbursable-healthcare-service/" updated: "2025-11-14" category: Research --- # The Evidence-Base for Neurofeedback as a Reimbursable Healthcare Service to Treat Attention Deficit/Hyperactivity Disorder By H. Edmund Pigott, Ph.D.,a Lindsay De Biase, Ph.D.,b Eugenia Bodenhamer-Davis, Ph.D.c & Richard E. Davis, M.S.d [The Evidence-Base for Neurofeedback as a Reimbursable Healthcare Service to Treat Attention Deficit/Hyperactivity Disorder By H. Edmund Pigott, Ph.D.,a Lindsay De Biase, Ph.D.,b Eugenia Bodenhamer-Davis, Ph.D.c & Richard E. Davis, M.S.d.pdf](https://isnr.org/wp-content/uploads/2019/07/NFB-as-an-Evidence-Based-Treatment-for-ADHD.pdf) *Disclaimer: The content below was generated with the assistance of AI and then reviewed and edited by BrainMaster Technologies, Inc. It is provided for educational and informational purposes only and does not constitute medical advice.* ## **Overview** This white paper comprehensively evaluates the scientific literature on **neurofeedback (NFB)** for **Attention-Deficit/Hyperactivity Disorder (ADHD)**. It reviews foundational neuroscience, controlled clinical trials, long-term outcomes, and comparisons to widely reimbursed treatments such as stimulant medication and behavior therapy. --- ## **Background: Limitations of Current ADHD Treatments** Large, federally funded studies—including the **NIMH Multimodal Treatment Study of ADHD (MTA)** and the **Preschool ADHD Treatment Study (PATS)**—found that: - Benefits of stimulant medication and behavior therapy **decline or do not sustain over time**. - Even with *optimal, multi-component care*, most children continued to meet diagnostic criteria for ADHD years later. - Many children experience adverse effects, incomplete response, or require escalating medication regimens. These findings underscore the need for additional, durable treatment options. --- ## **Foundations of Neurofeedback** Neurofeedback is a **behavioral learning method** using **real-time EEG measures** to help individuals improve self-regulation of brain activity. Key scientific foundations include: - **Operant conditioning research** demonstrating animals can regulate neuronal oscillations (e.g., sensorimotor rhythm or SMR). - Early human studies showing individuals can learn to modify theta, alpha, beta, SMR, and other EEG frequencies with measurable cognitive effects. - Established use of EEG-based operant conditioning in conditions such as epilepsy. --- ## **Evidence Supporting Neurofeedback for ADHD** ### **Seminal Studies** Early controlled reversal-design work by **Lubar & Shouse** demonstrated: - Increasing SMR reduced ADHD symptoms. - Decreasing SMR *worsened* symptoms. - Improvements persisted even after medication withdrawal. ### **Controlled Clinical Trials** Across more than **50 peer-reviewed studies**, including randomized and well-controlled trials, neurofeedback has shown: - Significant improvements in **inattention**, **impulsivity**, and **hyperactivity**. - Gains validated across **parent ratings**, **teacher ratings**, **performance tests**, and **neurophysiological measures**. - In several studies, neurofeedback outcomes were **equivalent to stimulant medication**. - Neurofeedback was superior to controls such as **sham feedback**, **EMG biofeedback**, **cognitive training**, and **wait-list conditions**. ### **Durability of Treatment Effects** Five studies—including two with **two-year follow-up**—showed that: - Treatment gains **persisted long-term** after neurofeedback ended. - Some children no longer met diagnostic criteria at follow-up. - In contrast, medication benefits generally cease when medication stops. --- ## **Meta-Analytic & Independent Evaluations** Neurofeedback has received strong external validation: - **Meta-analysis (Arns et al.)**: Large effect sizes for inattention and impulsivity; medium for hyperactivity. - **Hodgson et al. meta-analysis**: Neurofeedback twice as effective as six other non-pharmacological ADHD interventions. - **PracticeWise/American Academy of Pediatrics database**: Neurofeedback elevated to the **highest level of evidence-based support** for ADHD in 2012. --- ## **Practical Considerations for Clinical Use** - Typical course: **30–40 sessions** over 3–4 months. - No known adverse side effects reported for SMR, theta/beta, or SCP protocols in ADHD populations. - Treatment costs are “front-loaded” but may be **less expensive long-term** than years of medication and therapy. - EEG metrics allow for highly individualized treatment planning and progress tracking. --- ## **Policy Implications: Suitability for Reimbursement** Given: - Consistent clinical efficacy - Superiority to several active controls - Durability of benefits - Absence of documented adverse effects - Formal recognition by independent rating bodies The authors conclude that **neurofeedback meets criteria for a reimbursable, evidence-based intervention for ADHD**.